Book an Appointment
Emergency: 022-61305005
I want to find
My Health Records
Management Team

Theranostics

The term "theranostics" is derived from two words - therapy and diagnostics. It represents a cutting-edge approach to personalised cancer treatment. Molecular targets on cancer cells are first imaged using radioligands tagged with imaging tracers like F18 or Ga68 on a PET scanner. This imaging allows doctors to assess whether the receptors on the cancer cells are sufficiently overexpressed to be able to serve as targets for therapeutic delivery.  If suitable, the same ligand used to “see” the target is then used to “treat” it, delivering Beta or Alpha particles directly to the cancer cells. This “see and treat” approach is the foundation of highly personalised, targeted cancer therapy.

For therapies involving Lu177 and Ac225, treatment is administered through an intravenous injection. It is a painless procedure with minimal or no side effects. Patients are usually admitted for a day for the purpose of administering amino acid infusions or saline along with the TRT, better monitoring of patient post therapy, and acquiring a post therapy scan at 24 hours.

Radio-iodine therapy for thyroid cancer is given orally as a small liquid dose. It is painless, and the admission is done for one or two days primarily for the sake of radiation safety and avoiding exposure of patients’ family to the radiation.

The Department of Nuclear Medicine at Sir H. N. Reliance Foundation Hospital (RFH) has recently inaugurated its dedicated Targeted Radionuclide Therapy ward with experienced specialists offering comprehensive guidance, follow-up care, and the highest standard of care in molecular radiotargeted therapies.

Patients receiving high dose Iodine I-131 therapy are housed in specially designed isolation rooms for one or two days after therapy. The therapy wards meet the strict safety requirements approved by the Atomic Energy Regulatory Board (AERB) while ensuring patient comfort during their stay.

Bottom to top